A recent cost-effectiveness analysis addressed the question of the appropriate age for the start and end of screening colonoscopies.
Liver transplantation is a rapidly developing field. Advanced technologies, like AI, will improve access, outcomes, and offer more personalized care.
Tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma.
Auto-SCT did not improve mantle cell lymphoma with undetectable minimal residual disease outcomes after induction therapy.
Daratumumab plus lenalidomide had superior PFS outcomes vis-a-vis lenalidomide plus dexamethasone in frail patients with untreated MM.
Allo-SCT was more efficacious than standard-of-care in paediatric patients with sickle cell anaemia and abnormal cerebral artery velocities.
For VTE patients who needed extended anticoagulation, a reduced DOAC dose did not meet non-inferiority criteria for efficacy, compared to full DOACs.
Three novel mezigdomide-based triplet therapies seem tolerated and associated with anti-tumour activity in patients with relapsed or refractory MM.
Axicabtagene ciloleucel was associated with durable responses and long-term survival in relapsed or refractory indolent non-Hodgkin lymphoma.
A man in his 60s enters the ER after two fainting spells on the same day. The previous night he was woken up by severe palpitations. How to proceed?
Uproleselan + chemotherapy did not outperform chemotherapy alone for relapsed or refractory AML; but authors saw interesting trends in subgroups.
Daratumumab reduced progression to multiple myeloma and prolonged overall survival in patients with high-risk smouldering MM.
The investigational therapy GLPG5101 was associated with high response and a favourable safety profile in relapsed or refractory non-Hodgkin lymphoma.
Rilzabrutinib improved efficacy and QoL outcomes over placebo with a favourable safety profile among heavily pre-treated adults with immune thrombocytopenia.
Revumenib continued to display promising anti-tumour activity among patients with relapsed or refractory KMT2Ar acute leukaemia.
Hydroxyurea was associated to a reduction in clinical adverse events and improvements in haematological parameters in the phase 2 PIVOT trial.
Daratumumab plus VRd outperformed VRd alone in MRD-negativity rates for previously untreated multiple myeloma cases ineligible for transplant.
Adding blinatumomab to standard chemotherapy improved survival in paediatric patients with NCI standard-risk B-ALL at average or high relapse risk.
The French health authority updated its recommendations for improving HIV prevention and treatment. Here´s an overview of the main points.
Despite the decline in new HIV infections in recent decades, UNICEF is concerned about the gender gap in HIV prevalence.